

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

David Hung et al.

Atty. Docket: 005284.00214

Examiner: TBA

Group Art Unit: TBA

Serial No.: To Be Assigned
(Continuation of Serial No. 09/852,145)

Filed: August 19, 2003

For: Method For Differentiating Breast Ducts For Cancer Risk Status

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:


Pursuant to their duty of good faith and candor as set forth in 37 C.F.R. § 1.56(a) Applicants submit herewith the references cited on the attached PTO-1449 forms.

Copies of these references are not submitted herewith, but can be found in parent application file U.S. Serial No. 09/852,145.

Applicants respectfully request that the Examiner consider these references in connection with the search of the prior art required by 37 C.F.R. § 1.104.

It is believed that no fee is required to ensure consideration of the cited references by the Examiner. However, if a fee is deemed necessary, the Commissioner is authorized to charge our Deposit Account No. 19-0733.

Respectfully submitted,



Brian E. Hanlon

Reg. No. 40,449

Date: 8/19/03
Banner & Witcoff, Ltd.
Eleventh Floor
1001 G Street, N.W.
Washington, D. C. 20001-4597
(202) 824-3000

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	TBA
Filing Date	August 19, 2003
First Named Inventor	David Hung
Group Art Unit	TBA
Examiner Name	TBA
Attorney Docket Number	005284.00214

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

Application Number

TBA

Filing Date

August 19, 2003

First Named Inventor

David Hung

Group Art Unit

TBA

Examiner Name

TBA

Attorney Docket Number

005284.00214

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Petrakis, "Studies on the Epidemiology and Natural History of Benign Breast Disease and Breast Cancer Using Nipple Aspirate Fluid", Cancer Epidemiology, Biomarkers and Prevention, Vol. 2, pp 3-10, Jan/Feb 1993	
		Petrakis, "Nipple Aspirate Fluid in Epidemiological Studies of Breast Disease", Epidemiologic Reviews, Vol. 15 (1), pp 188-195, 1993	
		Sauter et al., "Nipple Aspirate Fluid: A Promising Non-Invasive Method to Identify Cellular Markers of Breast Cancer Risk", British Journal of Cancer, Vol. 76 (4), pp 494-501, 1997	
		Sartorius, Breast fluid cells help in early cancer detection, JAMA Vol. 224 (6), pp 823-827, 1973	
		Papanicolaou et al, "Exfoliative Cytology of the Human Mammary Gland and Its Value in the Diagnosis of Cancer and Other Diseases of the Breast, Cancer, Vol. 11, pp 377-409, March/April 1958	
		Goodson et al, "Discharges and Secretions of the Nipple", The Breast: Comprehensive Management of Benign and Malignant Diseases, 2 nd Ed. Vol. 2, Bland & Kirby eds., pp 51-74, 1998	
		Sartorius et al., Cytologic Evaluation of Breast Fluid in the Detection of Breast Disease, Journal of the National Cancer Institute, Vol. 59(4), pp 1073-80, 1977	
		King et al, Nipple Aspirate Cytology for the Study of Breast Cancer Precursors, Journal of the National Cancer Institute, Vol. 71(6), pp. 1115-21, 1983	
		Wensch, Breast Cancer Incidence in Women with Abnormal Cytology in Nipple Aspirates of Breast Fluid, Am. J. Epidemiology, Vol. 135(2), pp 130-141	

Examiner
Signature

Date

Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.